A patient preference and satisfaction study of ciclesonide nasal aerosol and
mometasone furoate aqueous nasal spray in patients with perennial allergic
rhinitis.
Author(s): Berger WE(1), Prenner B, Turner R, Meltzer EO.
Affiliation(s): Author information:
(1)Allergy and Asthma Associates of Southern California, Mission Viejo, California,
USA.
Publication date & source: 2013, Allergy Asthma Proc. , 34(6):542-50
Patients' preference and satisfaction with their nasal allergy medications may be
influenced by their sensory attributes. This study evaluates patient preference
and satisfaction with ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA)
compared with mometasone furoate aqueous nasal spray (MFNS). Symptomatic subjects
with perennial allergic rhinitis (PAR) were randomized to CIC-HFA at 74
micrograms or MFNS at 200 micrograms q.d. in an open-label, two-period, crossover
study. Subject preference was recorded as total preference score (TPS; average of
17 individual preference items) at the end of treatment period 2, and
satisfaction was assessed with a 76-item, self-administered instrument at
baseline and at the end of each 2-week treatment period. The primary assessments
were TPS and regimen attributes composite satisfaction score composed of two of
nine satisfaction subscales: sensory impact (including medication running out of
the nose, medication running down the throat, and impact on smell and taste) and
regimen management (comprised of issues relating to dosing and ability to
remember to take medication). Two hundred ninety-four subjects completed the
study. A total of 68.1% of subjects preferred CIC-HFA (p < 0.0001 versus MFNS),
with a mean TPS of 68.3 versus 31.7 for the MFNS group. The regimen attributes
composite satisfaction score significantly (p < 0.0001 for each treatment period)
favored CIC-HFA versus MFNS at the end of treatment period 1 (85.5 vs 77.6) and
treatment period 2 (83.0 versus 73.5), respectively. In this study, subjects
reported higher preference for and satisfaction with CIC-HFA compared with MFNS,
suggesting significant differences in patient perception of attributes in favor
of CIC-HFA. Clinical trial registration URL and registration number:
www.clinicaltrials.gov/ct2/show/NCT01401465.
|